Fidanacogene elaparovovec may reduce bleeding in men with hemophilia B
1. In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of bleeding in adult men ...
Tag: Hemophilia B
#VisualAbstract: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B is Superior to Prophylaxis
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
Click to view this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Once-a-month fitusiran reduces bleeding rates in patients with hemophilia A and B with inhibitors
1. Annualized bleeding rate was reduced by 91% in the fitusiran prophylaxis group compared to the bypassing agents on-demand group. ...
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B
1. Etranacogene dezaparvovec gene therapy was more effective than prophylactic factor IX infusion at reducing annualized bleeding rate amongst patients ...
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B
1. Hemophilia B patients treated with the adeno-associated virus (AAV) gene therapy produced dose-dependent sustained factor IX levels. 2. All ...